Most cited papers from CureVac (Germany)

CureVac (Germany)

What are the most cited papers from CureVac (Germany)?

The most cited paper from CureVac (Germany) is "Developing mRNA-vaccine technologies" (Thomas Schlake, Andreas Theß, Mariola Fotin‐Mleczek et al., 2012), with 638 citations. Next come "New Vaccine Technologies to Combat Outbreak Situations" (598) and "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial" (544).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 51 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Developing mRNA-vaccine technologies Thomas Schlake, Andreas Theß, Mariola Fotin‐Mleczek et al. · RNA Biology Open access	12 Oct 2012	638
2	New Vaccine Technologies to Combat Outbreak Situations Susanne Rauch, Edith Jasny, Kim E. Schmidt et al. · Frontiers in Immunology Open access	19 Sep 2018	598
3	Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial Martin Alberer, Ulrike Gnad-Vogt, Henoch Sangjoon Hong et al. · The Lancet	25 Jul 2017	544
4	Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals Andreas Theß, Stefanie E. Grund, Barbara L. Mui et al. · Molecular Therapy Open access	8 Jun 2015	528
5	Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection Benjamin Petsch, Margit Schnee, Annette B. Vogel et al. · Nature Biotechnology	18 Nov 2012	470
6	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients Benjamin Weide, Steve Pascolo, Birgit Scheel et al. · Journal of Immunotherapy	21 May 2009	384
7	Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity Mariola Fotin‐Mleczek, Katharina M. Duchardt, Christina Lorenz et al. · Journal of Immunotherapy	11 Dec 2010	339
8	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Hubert R Kübler, Birgit Scheel, Ulrike Gnad-Vogt et al. · Journal for ImmunoTherapy of Cancer Open access	13 Jun 2015	294
9	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation Adriana Bastidas et al. · JAMA Open access	9 Jul 2019	269
10	Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines Johannes Lutz, Sandra Lazzaro, Mohamed Habbeddine et al. · npj Vaccines Open access	10 Oct 2017	263
11	Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA Benjamin Weide, Jean‐Philippe Carralot, Anne Reese et al. · Journal of Immunotherapy	Feb 2008	263
12	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis Alemnew F. Dagnew et al. · The Lancet Infectious Diseases Open access	6 Aug 2019	261
13	Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Alexandros Papachristofilou et al. · Journal for ImmunoTherapy of Cancer Open access	8 Feb 2019	230
14	Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients Susanne Malaika Rittig, Maik Haentschel, Katrin J Weimer et al. · Molecular Therapy Open access	28 Dec 2010	224
15	A novel, disruptive vaccination technology Karl‐Josef Kallen, Regina Heidenreich, Margit Schnee et al. · Human Vaccines & Immunotherapeutics Open access	6 Aug 2013	223
16	Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging Kevin E. Lindsay, Sushma M. Bhosle, Chiara Zurla et al. · Nature Biomedical Engineering	Apr 2019	222
17	An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs Margit Schnee, Annette B. Vogel, Daniel Voß et al. · PLoS neglected tropical diseases Open access	23 Jun 2016	218
18	A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer Martin Sebastian et al. · Cancer Immunology Immunotherapy Open access	15 Feb 2019	213
19	Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial Cassandra Aldrich, Isabel Leroux‐Roels, Katell Bidet Huang et al. · Vaccine Open access	22 Jan 2021	210
20	Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent Jochen Probst, Benjamin Weide, Birgit Scheel et al. · Gene Therapy	3 May 2007	210
21	Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA Birgit Scheel, Regina Teufel, Jochen Probst et al. · European Journal of Immunology	15 Apr 2005	203
22	Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial Peter Vink et al. · Clinical Infectious Diseases Open access	28 Feb 2019	201
23	Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response Darin Edwards, Edith Jasny, Heesik Yoon et al. · Journal of Translational Medicine Open access	3 Jan 2017	189
24	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial Peter G. Kremsner et al. · The Lancet Infectious Diseases Open access177 authors	23 Nov 2021	176
25	Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-α Induction by CpG-A in Plasmacytoid Dendritic Cells Miren Kerkmann, Lilian T. Costa, Christine E Richter et al. · Journal of Biological Chemistry Open access	26 Feb 2005	174
26	Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model Taihua Yang et al. · Journal of Hepatology Open access	25 Aug 2021	173
27	mRNA mediates passive vaccination against infectious agents, toxins, and tumors Moritz Thran, Jean Mukherjee, Marion Pönisch et al. · EMBO Molecular Medicine Open access	9 Aug 2017	172
28	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents Susanne Rauch, Nicole Roth, Kim Schwendt et al. · npj Vaccines Open access	16 Apr 2021	167
29	Messenger RNA-based vaccines Steve Pascolo · Expert Opinion on Biological Therapy	Aug 2004	154
30	Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway Christina Lorenz, Mariola Fotin‐Mleczek, Günter Dietmar Roth et al. · RNA Biology Open access	Jul 2011	151
31	Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines Jean‐Philippe Carralot, Jochen Probst, Ingmar Hoerr et al. · Cellular and Molecular Life Sciences Open access	Sep 2004	149
32	Immunostimulating capacities of stabilized RNA molecules Birgit Scheel, Sybilla Braedel, Jochen Probst et al. · European Journal of Immunology	Feb 2004	141
33	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer Martin Sebastian, Alexandros Papachristofilou, Christian Weiß et al. · BMC Cancer Open access	6 Oct 2014	141
34	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine Makda S. Gebre et al. · Nature Open access	18 Nov 2021	138
35	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 Peter G. Kremsner et al. · Wiener klinische Wochenschrift Open access	10 Aug 2021	135
36	mRNA as novel technology for passive immunotherapy Thomas Schlake, Andreas Theß, Moritz Thran et al. · Cellular and Molecular Life Sciences Open access	17 Oct 2018	131
37	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours Mark Ross Middleton, Emma Jane Dean, Thomas R. Jeffry Evans et al. · British Journal of Cancer Open access	26 May 2021	127
38	A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs Karl‐Josef Kallen, Andreas Theß · Therapeutic Advances in Vaccines Open access	6 Nov 2013	127
39	A thermostable messenger RNA based vaccine against rabies Lothar Stitz, Annette B. Vogel, Margit Schnee et al. · PLoS neglected tropical diseases Open access	7 Dec 2017	119
40	Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA Birgit Scheel, Steffen Aulwurm, Jochen Probst et al. · European Journal of Immunology	Oct 2006	109
41	Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect Mariola Fotin‐Mleczek, Kai Zanzinger, Regina Heidenreich et al. · The Journal of Gene Medicine Open access	20 Jan 2012	105
42	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours Geoffrey Ira Shapiro, Robert Wesolowski, Craig Devoe et al. · British Journal of Cancer Open access	26 May 2021	104
43	Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers Peter G. Kremsner et al. · medRxiv PreprintOpen access	9 Nov 2020	103
44	Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity Aleksandra Kowalczyk, Fatma Doener, Kai Zanzinger et al. · Vaccine	19 Jun 2016	102
45	Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies Nicole S. Armbruster, Edith Jasny, Benjamin Petsch · Vaccines Open access	27 Sep 2019	97
46	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer Sebastian M. Dieter et al. · Cell Reports Open access	Jul 2021	94
47	mRNA: A Novel Avenue to Antibody Therapy? Thomas Schlake, Moritz Thran, Katja Fiedler et al. · Molecular Therapy Open access	5 Mar 2019	92
48	mRNA Cancer Vaccines Katja Fiedler, Sandra Lazzaro, Johannes Lutz et al. · Recent results in cancer research/Recent Results in Cancer Research Book chapter	2016	86
49	Characterization of the ribonuclease activity on the skin surface Jochen Probst, Sonja Brechtel, Birgit Scheel et al. · Genetic Vaccines and Therapy Open access	29 May 2006	86
50	A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile Regina Heidenreich, Edith Jasny, Aleksandra Kowalczyk et al. · International Journal of Cancer	22 Dec 2014	83

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.